v3.25.1
Revenue
3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue

Note 4. Revenue

 

The following tables present product net sales disaggregated by Channel and Geographic Market (in thousands):

 

Channel:  2025   2024 
   Three months ended March 31, 
Channel:  2025   2024 
Rx gammaCore – VA  $4,721   $3,875 
Rx gammaCore - U.S. Commercial   289    433 
Outside the United States   513    449 
Truvaga   1,106    385 
Total before TAC-STIM   6,629    5,142 
TAC-STIM   90    301 
Total Net Sales  $6,719   $5,443 

 

Product revenue  2025   2024 
Geographic Market:  Three months ended March 31, 
Product revenue  2025   2024 
United States  $6,206   $4,994 
United Kingdom   451    385 
Other   47    45 
License revenue          
Japan   15    19 
Total Net Sales  $6,719   $5,443 

 

The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Agreed upon payment terms with customers are within 30 days of shipment. Accordingly, contracts with customers do not include a significant financing component.